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Background and Aims 
p53 immunohistochemistry (IHC) has high specificity for TP53 mutation in 
ovarian carcinoma. Four molecular subtypes of endometrial carcinoma (EC) have 
been identified; accuracy of p53 IHC as a surrogate for TP53 mutation and 
thereby for serous-like EC is not established. We aimed to test whether p53 IHC 
predicts TP53 mutation in EC biopsies, universally and/or as part of a molecular 
classification algorithm and to compare interpretation results of p53 IHC 
between laboratories. 
 
Methods 
200 EC biopsies were selected from 5 histopathology laboratories to include 
serous:non-serous high grade:G1-2 endometrioid EC in a 2:1:1 ratio. Local p53 
IHC results were compared to central reference results. Central p53 IHC results 
were compared to tagged-amplicon NGS TP53 sequencing results.  
 
Results  
There was 95% complete concordance between local and central p53 IHC 
results. On preliminary results, deleterious TP53 mutations were detected in 
104/170 cases (excluding cases with failed analysis (n=23) and those showing 
heterogeneous p53 IHC (n=7)). Correlation between TP53 mutation and p53 IHC 
(Table 3) shows 91% accuracy (sensitivity 90.4%; specificity 91.2%). Correlation 
between TP53 mutation and p53 IHC as part of an algorithm, ie after exclusion of 
mismatch repair defective and DNA polymerase epsilon exonuclease domain 
(POLE) mutant cases, shows 93% accuracy (sensitivity 96.6%; specificity 
84.8%). 
 
Conclusions 
p53 IHC shows excellent inter-laboratory/inter-observer agreement in EC 
biopsy specimens. Our preliminary results suggest that p53 IHC is a robust 
biomarker of ‘serous-like’ EC in biopsy material, especially as part of an 
algorithm. 
 
 
 
 
 
 
